found that E18-truncated variant of FGFR2 (FGFR2ΔE18) acts as a potent single-driver alteration in cancers, whereas the tumourigenic abilities of full-length FGFR2 variant depend on cooperating driver genes [56]. This evidence concerns the gene FGFR2 and cancer.